Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Closure Medical (CLSR) fomerly Tri-Point Medical (TPMC) -- Ignore unavailable to you. Want to Upgrade?

To: David S. who wrote (132)	3/24/1998 7:38:00 PM
From: chum slury	Respond to of 184

I just received the latest edition of Family Practice News today Dated March 15. Closure Medical is featured on the front page.(\|Main article) There is also a before and after picture of a laceration above the eye. The results looked pretty good. I briefly asked my wife, who is in family practice, if this could take off. She thought it has good potential. Especially with young children who have cuts to close. Think of how much less trama is inflicted to the child with this vs. stitches. I believe that public support could be strong. If I had a choice I would pick this over stitches for my child. You mentioned J&J, I have not been following the stock until I saw the article that came out today. Is J&J working on something else? (I'm assuming not.)

To: David S. who wrote (132)	4/7/1998 6:42:00 AM
From: JYatsu	Read Replies (1) \| Respond to of 184

I guess I miss your point. Certainly J&J will be looking at other products, however they believe they have a significant product in Dermabond. Enough that they have cancelled a national sales meeting and replaced it with a product launch. I still believe the idea of first to market is a significant advantage here. Further more having the better product doesn't always get you there, ie Sony Beta, Apple. What other company has a giant like J&J marketing its product? The buzz is that there is going to be a huge advertising blitz to compliment the product launch to sensitize the consumer. As for future products, I'd be interested in the development of internal glue, especially for use in solid organ work.

To: David S. who wrote (132)	4/7/1998 6:57:00 AM
From: JYatsu	Read Replies (1) \| Respond to of 184

Oh I neglected to mention that J&J is launching its internal lung sealant with another small company called Focal. This is available in Europe only but the clinical trials for the US market are underway. I don't think this will be as big a market as Dermabond but there is a market. If you ever had a patient with a airleak following lung surgery, and all you could do is wait it out. You would see that the market for this product is in preventing airleaks and thereby decreasing hospitalization rates. The insurance companies will be all for it. So I guess my point is that if J&J are investors in Dermabond/CLSR, its good enough for me. They (J&J) have expertise and time to evaluate these companies and products that we don't have. So Merry Xmas back at yah.